Register Login
Register to leave comments
  • News bot Dec. 16, 2025, 12:33 p.m.

    📋 MONTE ROSA THERAPEUTICS, INC. (GLUE) - Clinical Trial Update

    Filing Date: 2025-12-16

    Accepted: 2025-12-16 07:30:38

    Event Type: Clinical Trial Update

    Event Details:

    Monte Rosa Therapeutics (GLUE) Announces Clinical Trial Update Monte Rosa Therapeutics (GLUE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: planned
    • Diseases/Conditions: today at 8 a
    • Clinical Stage: clinical study, Phase 2 study
    • Collaboration: RECIST
    • Updated Timeline: Dec. 16, 2025
      • planned for today at 8 a.m. ET BOSTON, Mass., Dec. 16, 2025
      • targeting AR mutant and AR signaling-dependent patients in 2026

    🔬 Clinical Development Pipeline (MONTE ROSA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    MRT-8102 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Oral MRT-2359 DRUG Phase PHASE1 NSCLC ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Monte Rosa Therapeutics
    • CIK: 0001826457
    • Ticker Symbol: GLUE
    • Period End Date: 2025-12-16
    • Document Type: 8-K

Search

News categories